Abstract
Prolactin-secreting pituitary tumors (PRL) (prolactinomas) are the most prelevant pituitary tumors and its first line treatment are dopaminergic agonists (DA), being effective in about 80% of cases. However, the remaining 20% partial or total resistance to these drugs require alternative treatment. PRL binds to its receptor (PRLR), a member of the cytokine receptor family and activates si…